Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Various forms of the plant extract Tripterygium wilfordi Hook F (TwHF) have been used in
China as a remedy for inflammatory diseases, including rheumatoid arthritis. The purpose of
this study is to investigate how tolerable, safe, and effective TwHF is for patients with
rheumatoid arthritis. Investigators will compare the therapeutic effects of TwHF with
Sulfasalazine, an FDA-approved drug for arthritis.
Participants in this 24-week study must have had active rheumatoid arthritis for at least six
months. Approximately 120 patients will participate. Participants will be assigned to one of
two drug-treatment groups, TwHF or Sulfasalazine. They will be given the study drug at each
of six clinic visits and will be asked to take two capsules three times each day with meals
and water. During the clinic visits, investigators will obtain multiple blood samples; give
physical exams; assess swollen, tender, and painful joints; and administer x-rays.
Study participants will be compensated up to $260 for their involvement in this study.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)